Compare Abeona Therapeutics Inc (ABEO) vs Kraft Heinz Co (KHC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kraft Heinz Co — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Kraft Heinz Co trades at $24.94 (market cap $30.00B). The key difference: Kraft Heinz Co is far larger — about 80.4× Abeona Therapeutics Inc's market cap, and Kraft Heinz Co pays a 6.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KHC | |
|---|---|---|
Market Cap | $373.32M | $30.00B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $28.94 |
52-Week Low | $4.17 | $21.21 |
Enterprise Value | $228.22M | $47.04B |
Dividend Yield | — | 6.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Kraft Heinz (KHC) trades at $25.3, down 0.28% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported a net loss of $5.85 billion in 2025, driving negative profit margins, but maintains strong operating cash flow of $4.46 billion and a 6.4% dividend yield. Recent news highlights a global reorganization aimed at accelerating growth and a strategic partnership with Heineken.
KHC presents a mixed outlook: attractive valuation metrics (P/E 13.04, P/B 0.7) and bullish technicals support potential upside, but significant profitability challenges and a cautious analyst consensus (57% hold rating) indicate headwinds. Key risks include execution of the new operating structure and sustained negative earnings, while the high dividend yield offers income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
